TY - JOUR
T1 - The Impact of lncRNA Dysregulation on Clinicopathology and Survival of Breast Cancer
T2 - A Systematic Review and Meta-analysis
AU - Tian, Tian
AU - Wang, Meng
AU - Lin, Shuai
AU - Guo, Yan
AU - Dai, Zhiming
AU - Liu, Kang
AU - Yang, Pengtao
AU - Dai, Cong
AU - Zhu, Yuyao
AU - Zheng, Yi
AU - Xu, Peng
AU - Zhu, Wenge
AU - Dai, Zhijun
N1 - Publisher Copyright:
© 2018 The Authors
PY - 2018/9/7
Y1 - 2018/9/7
N2 - Dysregulation of multiple long non-coding RNAs (lncRNAs) was reported to play major roles in breast cancer (BC). Here we aimed to collect most of the relevant literature to assess the prognostic value of lncRNAs in BC. To this end, we systematically searched PubMed, Embase, Web of Science, Chinese National Knowledge Infrastructure (CNKI), and Wanfang to identify published articles on the associations of lncRNAs with clinicopathology and/or survival of BC. Via this searching, we identified 70 articles involving 9,307 BC patients and regarding 48 lncRNAs. The expression of 41 lncRNAs was related to one or more clinicopathological parameters of BC, including tumor size; lymph node metastasis; histological grade; TNM stage; and estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) statuses (p < 0.05). Dysregulation of 28 lncRNAs was associated with overall survival, and abnormal expression of 9 lncRNAs was linked to disease-free survival. Furthermore, the expression level of 3 lncRNAs was correlated with metastasis-free survival, 3 lncRNAs with relapse-free survival, and 3 lncRNAs with progression-free survival. Our analysis showed that multiple lncRNAs were significantly associated with BC clinicopathology and survival. A large-scale study is needed to verify the prognostic value of these lncRNAs in BC.
AB - Dysregulation of multiple long non-coding RNAs (lncRNAs) was reported to play major roles in breast cancer (BC). Here we aimed to collect most of the relevant literature to assess the prognostic value of lncRNAs in BC. To this end, we systematically searched PubMed, Embase, Web of Science, Chinese National Knowledge Infrastructure (CNKI), and Wanfang to identify published articles on the associations of lncRNAs with clinicopathology and/or survival of BC. Via this searching, we identified 70 articles involving 9,307 BC patients and regarding 48 lncRNAs. The expression of 41 lncRNAs was related to one or more clinicopathological parameters of BC, including tumor size; lymph node metastasis; histological grade; TNM stage; and estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) statuses (p < 0.05). Dysregulation of 28 lncRNAs was associated with overall survival, and abnormal expression of 9 lncRNAs was linked to disease-free survival. Furthermore, the expression level of 3 lncRNAs was correlated with metastasis-free survival, 3 lncRNAs with relapse-free survival, and 3 lncRNAs with progression-free survival. Our analysis showed that multiple lncRNAs were significantly associated with BC clinicopathology and survival. A large-scale study is needed to verify the prognostic value of these lncRNAs in BC.
KW - breast cancer
KW - clinicopathology
KW - long non-coding RNA
KW - prognosis
KW - survival
UR - https://www.scopus.com/pages/publications/85049315562
U2 - 10.1016/j.omtn.2018.05.018
DO - 10.1016/j.omtn.2018.05.018
M3 - 文章
AN - SCOPUS:85049315562
SN - 2162-2531
VL - 12
SP - 359
EP - 369
JO - Molecular Therapy Nucleic Acids
JF - Molecular Therapy Nucleic Acids
ER -
